DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT

Molecular Cancer Research

Volumn 7, Issue 4, 2009, Pages 581-591

  Dejmek, Janna ^a,b   Dirk Iglehart, J ^a,b   Lazaro, Jean Bernard ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; DACTINOMYCIN; DNA BINDING PROTEIN; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; HYDROXYUREA; MITOMYCIN C; NU 7026; PROTEIN KU86; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN SSRP1; PROTEIN SUBUNIT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FACT; UNCLASSIFIED DRUG; WERNER SYNDROME PROTEIN; WORTMANNIN; ANTINEOPLASTIC AGENT; CELL NUCLEUS ANTIGEN; EXODEOXYRIBONUCLEASE; HIGH MOBILITY GROUP PROTEIN; KU ANTIGEN; NUCLEAR PROTEIN; PRKDC PROTEIN, HUMAN; RECQ HELICASE; SSRP1 PROTEIN, HUMAN; TRANSCRIPTION ELONGATION FACTOR; WRN PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG BINDING; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ADENOCARCINOMA; BREAST TUMOR; CELL CULTURE; CELL SURVIVAL; CHROMATIN; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HELA CELL; IMMUNOBLOTTING; KIDNEY; METABOLISM; NUCLEOLUS; OVARY TUMOR; PHYSIOLOGY; RADIATION EXPOSURE;

ADENOCARCINOMA; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL NUCLEOLUS; CELL SURVIVAL; CELLS, CULTURED; CHROMATIN; CISPLATIN; DNA DAMAGE; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; EXODEOXYRIBONUCLEASES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HELA CELLS; HIGH MOBILITY GROUP PROTEINS; HUMANS; IMMUNOBLOTTING; KIDNEY; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; RECQ HELICASES; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 65549111786     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0049     Document Type: Article

References (37)

1. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998;34:1535-1542
2. Kilburn LS. 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. Clin Oncol (R Coll Radiol) 2008;20:35-39
3. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279
4. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-790
5. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008;14:1291-1295
6. Reinberg D, Sims RJ. 3rd de FACTo nucleosome dynamics. J Biol Chem 2006;281:23297-23301
7. Yarnell AT, Oh S, Reinberg D, Lippard SJ. Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin. J Biol Chem 2001;276:25736-25741
8. Hudson ME, Pozdnyakova I, Haines K, Mor G, Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 2007;104:17494-17499
9. Downs JA, Jackson SP. A means to a DNA end: the many roles of Ku. Nat Rev Mol Cell Biol 2004;5:367-378
10. Turchi JJ, Henkels K. Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase. J Biol Chem 1996;271:13861-13867
11. Sakamoto S, Nishikawa K, Heo SJ, Goto M, Furuichi Y, Shimamoto A. Werner helicase relocates into nuclear foci in response to DNA damaging agents and co-localizes with RPA and Rad51. Genes Cells 2001;6:421-430
12. Cheng WH, von Kobbe C, Opresko PL, et al. Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution. Mol Cell Biol 2003;23:6385-6395
13. Tembe V, Henderson BR. Protein trafficking in response to DNA damage. Cell Signal 2007;19:1113-1120
14. Burckstummer T, Bennett KL, Preradovic A, et al. An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods 2006;3:1013-1019
15. Andersen JS, Lam YW, Leung AK, et al. Nucleolar proteome dynamics. Nature 2005;433:77-83.
16. Higashiura M, Shimizu Y, Tanimoto M, Morita T, Yagura T. Immunolocalization of Ku-proteins (p80/p70): localization of p70 to nucleoli and periphery of both interphase nuclei and metaphase chromosomes. Exp Cell Res 1992;201:444-451
17. Zhang S, Hemmerich P, Grosse F. Nucleolar localization of the human telomeric repeat binding factor 2 (TRF2). J Cell Sci 2004;117:3935-3945
18. Bravo R, Small JV, Fey SJ, Larsen PM, Celis JE. Architecture and polypeptide composition of HeLa cytoskeletons. Modification of cytoarchitectural polypeptides during mitosis. J Mol Biol 1982;154:121-143
19. Olson MO, Dundr M. The moving parts of the nucleolus. Histochem Cell Biol 2005;123:203-216
20. Zhang S, Kohler C, Hemmerich P, Grosse F. Nuclear DNA helicase II (RNA helicase A) binds to an F-actin containing shell that surrounds the nucleolus. Exp Cell Res 2004;293:248-258
21. Kuhn A, Stefanovsky V, Grummt I. The nucleolar transcription activator UBF relieves Ku antigen-mediated repression of mouse ribosomal gene transcription. Nucleic Acids Res 1993;21:2057-2063
22. Kurki S, Peltonen K, Latonen L, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004;5:465-475
23. Karmakar P, Bohr VA. Cellular dynamics and modulation of WRN protein is DNA damage specific. Mech Ageing Dev 2005;126:1146-1158
24. Andersen JS, Lyon CE, Fox AH, et al. Directed proteomic analysis of the human nucleolus. Curr Biol 2002;12:1-11.
25. Abraham RT. PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst) 2004;3:883-887
26. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375-4382
27. Willmore E, de Caux S, Sunter NJ, et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004;103:4659-4665
28. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269:5241-5248
29. Chen BP, Chan DW, Kobayashi J, et al. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem 2005;280:14709-14715
30. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995;376:599-602.
31. Daniely Y, Borowiec JA. Formation of a complex between nucleolin and replication protein A after cell stress prevents initiation of DNA replication. J Cell Biol 2000;149:799-810.
32. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO Journal 2003;22:6068-6077
33. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene 2005;24:949-961
34. Comai L, Li B. The Werner syndrome protein at the crossroads of DNA repair and apoptosis. Mech Ageing Dev 2004;125:521-528
35. Heo K, Kim H, Choi SH, et al. FACT-mediated exchange of histone variant H2AX regulated by phosphorylation of H2AX and ADP-ribosylation of Spt16. Mol Cell 2008;30:86-97.
36. Durant S, Karran P. Vanillins - a novel family of DNA-PK inhibitors. Nucleic Acids Res 2003;31:5501-5512
37. Muramatsu M, Busch H. Studies on nucleolar RNA of the Walker 256 carcinosarcoma and the liver of the rat. Cancer Res 1964;24:1028-1034